Bayer's Cardiology Readout in Phoenix Meets a $2.2 Billion Ohio Bet

Bayer closed up 2.0% at EUR 43.82 as the FDA accepted its Kerendia filing; heart-failure data at the Phoenix meeting now take focus.

Bayer shares found firmer footing to close the week, climbing 2.0% to EUR 43.82 as European equities broadly recovered. The tailwind came from outside the company: softer crude prices, easing market yields and a well-received US Treasury auction combined to lift sentiment across the DAX. A day earlier, the stock had added 2.2% to EUR 43.90 on the back of regulatory news.

That regulatory news concerned Kerendia. The US Food and Drug Administration has accepted Bayer's supplemental filing for the kidney drug, which the company hopes to have approved for adults with chronic kidney disease who do not have diabetes. The active ingredient is finerenone, and the submission rests on the Phase III FIND-CKD trial, which enrolled 1,584 patients with non-diabetic kidney disease. Investigators found that adding finerenone to standard therapy significantly slowed the loss of kidney function and cut cardiovascular-renal events.

Acceptance, however, is not approval. The FDA has not set a target date for a final verdict, leaving investors to judge whether the data can support an unrestricted label expansion or whether further requests from the agency might stretch out the timeline. Kerendia is currently cleared in more than 100 countries, chiefly for chronic kidney disease linked to type 2 diabetes. Widening the indication to patients without diabetes would enlarge the addressable market considerably.

Phoenix Takes Center Stage

While the regulatory file works its way through Washington, attention this weekend shifts to the Heart Failure Society of America's annual meeting in Phoenix, running from October 9 to 12. Bayer has slated a late-breaking presentation plus five scientific posters covering heart failure and cardiac amyloidosis. For shareholders, the appearance marks the start of a decisive stretch: after weeks of market-driven losses, the clinical pipeline now has to demonstrate enough momentum to underpin the equity on fundamentals.

The central question is how quickly Bayer can open and secure new revenue streams in pharmaceuticals. The company's reliance on cardiology indications remains pronounced, and patent-protected blockbusters will eventually need replacing. Every setback — or any doubt about the commercial readiness of new therapeutic approaches — carries outsized weight at this stage. Should the Phoenix data land poorly with specialists, skepticism could return in short order.

Ohio and a New Chief Medical Officer

On the operational side, Bayer is pushing ahead with a major US expansion. In early October the group announced a $2.2 billion investment in a new production site in New Albany, Ohio. The plant is slated to make pharmaceutical active ingredients from 2031 and finished products from 2034, supported by roughly 600 permanent jobs. The project dovetails with a leadership reshuffle: just over a week ago, Dr. Christoph Koenen took over as Chief Medical Officer of the pharma division.

The bull case leans on these initiatives paying off. Strong reception for the Phoenix heart-failure and cardiac amyloidosis data would bolster the cardiology franchise, and combined with the finerenone filing it would hand optimistic investors fresh arguments for a fundamental re-rating. JPMorgan analysts rate the stock "Overweight" with a EUR 61 price target, a signal of confidence in the longer-term pipeline.

The Bear Case: Heavy Outlays, Slow Returns

Skeptics point to the remaining uncertainties in the approval process and the long runway before new revenue arrives. If the FDA demands extra data or writes a narrower target population than hoped, the planned expansion loses steam. Large projects such as the Ohio plant also require substantial upfront spending whose financial returns will not materialize until the next decade.

The most recent operating print offers a mixed picture. In the second quarter of 2026, Bayer returned to profit with earnings per share of EUR 0.23, reversing a loss of EUR 0.20 a year earlier. Quarterly revenue, however, rose just 1.24% year over year to EUR 10.87 billion. Should operating growth slow while regulatory decisions drag on, market doubt could resurface quickly. The recent rally, after all, rested on macroeconomic relief rather than new company successes.

Chart Levels and the November 3 Print

Near-term direction now hinges on defending the recent gains. As long as the shares hold above the 200-day moving average of EUR 43.25, the chance of stabilization remains intact. A sustained drop below that line would suggest the market views the past few days as a mere countermove, opening the door to a deeper correction.

The next hard catalyst is scheduled for November 3, 2026, when Bayer reports third-quarter results and hosts an investor video conference. Until then, the market's reaction to the cardiology data out of Phoenix is likely to set the tone.